IL1B and hyperlipidemia: The CANTOS trial demonstrated that specifically targeting IL-1β with the monoclonal antibody canakinumab reduced chronic low-grade inflammation and the incidence of cardiovascular events, independently of other factors such as hyperlipidemia [42].